Verax Biomedical Inc. v. American National Red Cross

  1. June 26, 2024

    Biotech Co. Allowed To Appeal Red Cross Antitrust Immunity

    The American Red Cross' immunity from antitrust allegations that it smothered competition for testing platelets for bacteria is back in play after a Massachusetts federal judge agreed Wednesday to let the biotech company suing the blood donation giant ask the First Circuit to revive its claims.

  2. May 06, 2024

    Biotech Co. Wants To Appeal Red Cross Antitrust Immunity

    A biotech company has told a Massachusetts federal court that giving the American Red Cross immunity from claims that it smothered competition in the platelet bacteria mitigation market is unprecedented and leaves the organization free to fix prices or buy up its competitors.

  3. January 22, 2024

    Red Cross Has Antitrust Immunity, Judge Rules

    A Boston federal judge ruled that the American Red Cross is immune from antitrust claims because of its federal charter and public functions, largely dismissing a suit alleging the organization smothered competition in the platelet bacteria mitigation market.

  4. August 16, 2023

    Red Cross Says DOJ Wrong On Antitrust Immunity

    The American National Red Cross told a Massachusetts federal court a host of government entities would be exposed to potential liability if the court accepts the U.S. Department of Justice's position that the group must face a biotech company's antitrust claims.

  5. August 04, 2023

    DOJ Says Red Cross Not Immune From Platelet Antitrust Suit

    The Justice Department said Friday the American National Red Cross is subject to federal antitrust laws, calling the nonprofit's defense to a Massachusetts biotech's lawsuit a "misreading of the law."

  6. May 23, 2023

    Biotech Co. Says Red Cross Plainly Violated Antitrust Law

    A biotech company defended its suit in Massachusetts federal court accusing the American National Red Cross of snuffing out competition in the platelet bacteria mitigation market, contending the case is straightforward and "presents textbook antitrust claims."

  7. April 18, 2023

    Red Cross Says Biotech's Antitrust Suit Makes No Sense

    The American Red Cross on Monday blasted a biotech company's suit claiming it's trying to snuff out competition in platelet bacteria mitigation, arguing the case "makes no sense" and would allow private companies to dictate the practices of humanitarian nonprofits.

  8. February 15, 2023

    Red Cross Hit With Antitrust Suit For Platelet Treatment Tying

    The American Red Cross has been accused by a biotech company of launching an illegal campaign to "smother" competition in the platelet bacteria mitigation market by tying its platelet sales to its own in-house contamination avoidance services.